BSE: 532540 NSE: Glenmark Pharmaceuticals ISIN: INE467B01029 SECTOR: IT Software Company Company’s Website: IPO Date & Price: July 29, 2004 | Rs.
Glenmark Pharmaceuticals Overview:
| Stock Symbol in NSE | Stock Symbol in BSE | Current Price | Market Cap. (Cr) | P/E Ratio | Current EPS |
|---|
Glenmark Pharmaceuticals Sector Performance and Peer Comparison with Sector Analysis:
Did You Know?
<Space for Feature Image>
- Glenmark Pharmaceuticals is the
- Its Belong to Group.
Balance Sheets & Profit & Loss Account:
| Year | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|
Glenmark Pharmaceuticals Share Price Forecast Based on Current Growth +5/-5:
Share Price and EPS Forecast Based on Current Average Growth Rates:
| Next 5 Years (CG) | Next 10 Years (CG) | Next 20 Years (CG) |
|---|
Share Price and EPS Forecast Based on Current Average Growth Rates Plus 5%:
| Next 5 Years (CG+5%) | Next 10 Years (CG+5%) | Next 20 Years (CG+5%) |
|---|
Share Price and EPS Forecast Based on Current Average Growth Rates Minus 5%:
| Next 5 Years (CG-5%) | Next 10 Years (CG-5%) | Next 20 Years (CG-5%) |
|---|
Glenmark Pharmaceuticals Quarterly Result, Date & Street Estimate:
| Stock Symbol in NSE | Share Name | Quarter Results | Year | Street Estimates | Profits | Growth |
|---|
Fundamental Analysis of Glenmark Pharmaceuticals :
Glenmark Pharmaceuticals Share Long Term Investment Price Target:
| Price | Qnt.Ratio | Long Term Investment Tagets |
|---|
Glenmark Pharmaceuticals Fundamentals SWAT Analysis by AMT
Strengths, Weaknesses, Opportunities, and Threats of Glenmark Pharmaceuticals
S
- Strengths Analysis will coming Soon.
W
- Weakness Analysis will coming Soon.
O
- Opportunity Analysis will coming Soon.
T
- Threats Analysis will coming Soon.
Where we can See Glenmark Pharmaceuticals in Next 5 Year, 10 Year & 20 Year?
Technical Analysis of Glenmark Pharmaceuticals :
Glenmark Pharmaceuticals Share Weekly Swing Trading Price Target:
| Demand And Supply Zone | Support Levels | Support Price | Resistance Levels | Resistance Price |
|---|
Glenmark Pharmaceuticals Share Today Intraday Price Target:
| IntradayTarget Today [Short Selling] | IntradayTarget Today [Long Buying] |
|---|
FAQ on Glenmark Pharmaceuticals :
Yes, Glenmark Pharmaceuticals is India Number-1 IT Software company, with lots business potential in next few year. Its Fundamentally strong Stock we recommend to buy at around 20-25 PE Ration price target. Anyway This company is quite famous for Good Dividends.
Glenmark Pharmaceuticals is a Debt free company. Its can easily survived any down turn for 5-10 Quarter business growth.
Currently Glenmark Pharmaceuticals is Trading at P/E Ratio which is
Both and working as a
Do to Covid-19 pandemic Glenmark Pharmaceuticals Share drastically fall.
Its depend on when you and at what price you have buy this share, Glenmark Pharmaceuticals at 20-25 P/E Ration is a excellent buy call for long Term Investment.
Glenmark Pharmaceuticals ‘s Products/Projects:
| Products/Projects | Description/Valuation |
| A. | |
| B. | |
| C. |
IPO, Split, Bonus, Dividend Buyback History:
Glenmark Pharmaceuticals First IPO was initiate on July 29, 2004. equity shares were put on sale during the IPO with a price band of Rs -Rs per equity share.
[ninja_tables id=”79096″
Company Profile:
| CEO Name | Glenn Mario Saldanha |
| CFO Name | V S Mani |
| CEO Salary | 122.35M |
| Company Address | 52, Hem Chandra Naskar Rd, Sura Cross Lane, Phool Bagan, Beleghata, Kolkata, West Bengal 700010 |
| Contact Number | 1-888-721-7115 40189999, 40189879 |
| Email Address | [email protected] |
Declaration: Investing in the Stock market is full of Risky. AllMoneyTips.COM doesn’t give any guarantee or warranted on its investment advice. Do your research before investing in the stock market. Our Forecast and buying selling levels of stocks is based on price action and demand and supply zone. There is no guarantee come with our prediction. Take it as advice only. We are not responsible for your losses on your investments.